Jinhe Biotechnology Co Ltd (002688) - Total Liabilities
Based on the latest financial reports, Jinhe Biotechnology Co Ltd (002688) has total liabilities worth CN¥2.99 Billion CNY (≈ $436.83 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002688 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Jinhe Biotechnology Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Jinhe Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Jinhe Biotechnology Co Ltd total assets.
Jinhe Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinhe Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Advanced Digital Technology Co Ltd
SHE:300541
|
China | CN¥1.63 Billion |
|
Chong Kun Dang Pharmaceutical
KO:185750
|
Korea | ₩803.02 Billion |
|
Spearhead Integrated Marketing
SHE:300071
|
China | CN¥608.62 Million |
|
China Wuyi Co Ltd
SHE:000797
|
China | CN¥16.52 Billion |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
China | CN¥399.05 Million |
|
Zhejiang Huada New Materials Co Ltd
SHG:605158
|
China | CN¥6.70 Billion |
|
CCP Contact Probe Co Ltd
TWO:6217
|
Taiwan | NT$3.50 Billion |
|
iQIYI Inc
NASDAQ:IQ
|
USA | $33.15 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Jinhe Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002688 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinhe Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinhe Biotechnology Co Ltd (2008–2024)
The table below shows the annual total liabilities of Jinhe Biotechnology Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion ≈ $461.05 Million |
+7.27% |
| 2023-12-31 | CN¥2.94 Billion ≈ $429.79 Million |
+41.18% |
| 2022-12-31 | CN¥2.08 Billion ≈ $304.42 Million |
+52.07% |
| 2021-12-31 | CN¥1.37 Billion ≈ $200.19 Million |
-15.91% |
| 2020-12-31 | CN¥1.63 Billion ≈ $238.07 Million |
+5.82% |
| 2019-12-31 | CN¥1.54 Billion ≈ $224.97 Million |
-1.19% |
| 2018-12-31 | CN¥1.56 Billion ≈ $227.69 Million |
+17.64% |
| 2017-12-31 | CN¥1.32 Billion ≈ $193.54 Million |
+22.67% |
| 2016-12-31 | CN¥1.08 Billion ≈ $157.78 Million |
+29.80% |
| 2015-12-31 | CN¥830.68 Million ≈ $121.55 Million |
+47.68% |
| 2014-12-31 | CN¥562.50 Million ≈ $82.31 Million |
+381.57% |
| 2013-12-31 | CN¥116.81 Million ≈ $17.09 Million |
-16.46% |
| 2012-12-31 | CN¥139.83 Million ≈ $20.46 Million |
-58.44% |
| 2011-12-31 | CN¥336.44 Million ≈ $49.23 Million |
-8.85% |
| 2010-12-31 | CN¥369.09 Million ≈ $54.01 Million |
-12.65% |
| 2009-12-31 | CN¥422.56 Million ≈ $61.83 Million |
+8.73% |
| 2008-12-31 | CN¥388.63 Million ≈ $56.87 Million |
-- |
About Jinhe Biotechnology Co Ltd
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.